BAYER AG NA
Commented by Armin Schulz on November 17th, 2026 | 19:35 CET
Bayer, Cardiol Therapeutics, Novartis – Biotech stocks and pharmaceutical giants in the race for the heart
Created and Published on Behalf of Cardiol Therapeutics
Cardiology is one of the most exciting fields in the pharmaceutical industry. Four days in Chicago have shown just how much is happening in cardiovascular medicine. From November 6 to 9, pharmaceutical giants and small biotech companies gathered at the American Heart Association Scientific Sessions annual congress with a shared goal: to improve care for patients with cardiovascular disease. The major players bring experience and capital, while smaller companies often contribute fresh ideas. When a company succeeds in securing regulatory approval, investors stand to benefit. This interplay is precisely what makes the market so interesting for investors. We therefore take a closer look at Bayer, Cardiol Therapeutics, and Novartis.
ReadCommented by Fabian Lorenz on November 13th, 2026 | 05:41 CET
Singulus shares +1,500% thanks to Elon Musk! What are Almonty and Bayer doing?
Singulus shares have gained more than 1,500% this year. One major reason the machinery manufacturer has gone from a bankruptcy candidate to a high-flyer is Elon Musk. The first major order from his space company, SpaceX, has been placed, and analysts expect more. Almonty shares were also among the year's high-flyers until April. Since then, the stock has corrected sharply. This could offer investors an attractive opportunity to buy or add to their holdings. Analysts expect the tungsten producer to generate earnings of USD 2.76 per share next year. The shares are currently trading just above USD 8. Bayer shares are at a multi-year high. Analysts have raised the price target.
ReadCommented by Carsten Mainitz on November 10th, 2026 | 05:45 CET
Exciting pharma duel: Who will take off now - BioNxt Solutions, Bayer or Novo Nordisk?
New active ingredients, expanded indications and more user-friendly dosage forms are driving momentum in the global pharmaceutical market. BioNxt Solutions is focusing on novel oral dissolvable films and working towards regulatory and clinical breakthroughs. Industry heavyweights Bayer and Novo Nordisk have recently reported solid quarterly results. Bayer has already overcome several challenges and raised its outlook. At the same time, Novo Nordisk is impressively demonstrating how innovative forms of administration in obesity treatment can achieve soaring commercial success. Where do the most attractive opportunities for investors lie following the latest developments?
ReadCommented by Lars Winter on November 6th, 2026 | 05:35 CET
Gold potential, pharma comeback and AI boom: Lahontan Gold, Bayer and AMD in Focus
A gold project with enormous return potential, a pharmaceutical group with fresh tailwinds and a chip designer on course for records: Lahontan Gold, Bayer and AMD are currently delivering exciting news. The leverage is particularly strong at the Canadian gold developer, whose Santa Fe project promises enormous growth potential according to the PEA. Bayer, meanwhile, recently raised its earnings targets, while AMD is benefiting from the expansion of data centres. We examine where the opportunities now lie and where investors need to look more closely - three interesting stocks under review.
ReadCommented by Matthias Schomber on November 5th, 2026 | 05:35 CET
Power Shift in the US! Why Bayer Is Booming, TeamViewer Is Plunging and Almonty Industries Could Be on the Verge of a Major Rally!
Power shift in Washington! The Democrats have recaptured the Senate in the US midterm elections and probably the House of Representatives too. For Donald Trump, this means sharing power for the rest of his term, as legislation, taxes and indirectly tariffs will no longer pass quite so easily without the Democrats. The question for the stock market now is whether investors see the setback for the Trump agenda as a threat or a relief. Sectors that depend on regulation, government spending and trade policy in particular could now see greater volatility. Developments in international financial markets are coming thick and fast these days! While Bayer is sending a strong signal with surprisingly strong quarterly results and raised full-year targets, software provider TeamViewer is causing alarm in the SDAX with a sharp slump and a lowered outlook. Meanwhile, an exciting story looks set to unfold in the tungsten sector with Almonty. Following a rapid rise, the shares are undergoing a strong and intense consolidation, which savvy investors could nevertheless see as a rare and attractive buying opportunity. Find out below which stocks have genuine recovery potential following the latest news, where the potential risks lie in detail and how best to position your portfolio for the coming weeks and months. A look behind the scenes suggests markets may be undergoing a complete reassessment right now.
ReadCommented by André Will-Laudien on November 2nd, 2026 | 05:43 CET
The Biotech breakout: Bayer and Eli Lilly flex their muscles - are Novo Nordisk, Evotec and BioNxt the next winners?
That was a week of selling on the NASDAQ! The technology index lost a full 5% in its renewed attempt to exceed the 30,000-point mark. Chip stocks, which had previously performed excellently, came under considerable pressure, followed by subdued figures from Alphabet, Microsoft and, most recently, Intel. The result was hefty double-digit losses; this sector has not seen this much uncertainty in a long time. Things are very different in the biotech sector. At 7,319 points, the underlying NASDAQ Biotech Index only narrowly missed its all-time high of 7,458 points. Leading players such as Bayer and Eli Lilly brought a breath of fresh air to the sector, which could now significantly outperform other industries towards the end of the year. We take a closer look at some of the protagonists.
ReadCommented by Fabian Lorenz on October 31st, 2026 | 05:38 CET
Bayer and MustGrow Are Making Concrete Progress, While CTS Eventim Is Entering an Interesting Phase
Created and published on behalf of MustGrow Biologics Corp.
Is CTS Eventim facing turbulent times? An activist US investor is applying pressure, which is unlikely to please founder and major shareholder, Klaus-Peter Schulenberg. The entrepreneur is known for his independent-minded approach and reluctance to compromise. The situation could have implications for the company's share price. MustGrow could also be approaching a significant turning point. Analysts see considerable upside potential, and the company is benefiting from its partnership with Bayer. The two companies recently even held a joint webcast. Bayer itself has also reported positive news, including an important regulatory approval in China.
Commented by André Will-Laudien on October 29th, 2026 | 05:39 CET
Life Sciences in Focus as Sector Rotation Takes Shape: Bayer, Vidac Pharma, Eli Lilly, Novo Nordisk and Evotec in 2027
AI is consolidating, and the Life Sciences sector is firing up its first turbo: Rising healthcare spending, the demographic ageing wave and a veritable wave of innovation are catapulting the industry straight into a multi-year supercycle – and now the major players are reallocating their capital. AI and high-tech have delivered their returns, and now the new outperformers for 2027 are stepping into the spotlight. The catch: after years of heavy losses, most stocks are trading close to their 5-year lows. That will not last! Some companies are already waiting in the wings, with the painful restructuring completed. Leading the way, Novo Nordisk continues its relentless advance as the undisputed flagship of the global obesity and diabetes wave. A genuine hidden gem for return hunters is Vidac Pharma. Through its research into the Warburg effect, the biotech firm is revolutionising cancer therapy and, as a classic high-beta play, adds a dash of spice to opportunity-focused portfolios. The giant Bayer is also back, consistently using the current valuation lull as a major entry opportunity to ignite the next phase of growth with a revamped pipeline. The power quartet is completed by Hamburg-based drug discovery company Evotec, which benefits directly from demand for complex therapies as an indispensable infrastructure and development partner. Those who want to stay ahead in the coming Life Sciences boom need to set the course for their portfolio now!
ReadCommented by Carsten Mainitz on October 28th, 2026 | 05:30 CET
Sow First, Reap Later! Exciting Developments at MustGrow, Bayer and K+S – Who Is Best Positioned?
Created and Published on Behalf of MustGrow Biologics Corp.
Fewer chemicals, healthier soils and higher yields. Agriculture is looking for solutions that combine environmental protection and economic viability. Political support appears to be emerging from Brussels. The EU plans to approve biological crop protection products more quickly and reduce the administrative burden. However, the Council and the European Parliament still need to reach an agreement. At least the direction is right, which could open new opportunities for companies like MustGrow. The Canadians develop mustard-based agricultural products and cooperate with Bayer on biological crop protection through a licensing partnership. The first development milestone payment was made under this partnership in the summer. Bayer's agricultural division focuses on seeds and crop protection. K+S supplies potassium- and magnesium-based fertilisers for agriculture. Ultimately, all three companies face similar challenges: new and existing products must improve yields per hectare while remaining economically viable for farmers. Which stock offers the most value for investors?
ReadCommented by André Will-Laudien on October 27th, 2026 | 05:34 CET
Strong Stock Gains from the Green Transition! How Coca-Cola, Bayer, MustGrow and PepsiCo Are Preparing for the Future
Created and Published on Behalf of MustGrow Biologics Corp.
Despite regulatory progress, global food security remains precarious. According to a recent report by Welthungerhilfe and partner organisations, around a tenth of the world's population suffers from acute malnutrition. Global crises such as climate change and armed conflicts are further exacerbating the situation. Large corporations must therefore go beyond statutory minimum standards and guarantee fair purchase prices to strengthen the resilience of smallholder farms. Only by firmly linking corporate due diligence with sustainable farming practices can the UN Sustainable Development Goal of ending hunger be achieved in the long term. To steer multinational corporations' market power toward more sustainable practices, the European Union is increasingly turning to regulation. A key instrument is the EU Corporate Sustainability Due Diligence Directive (CSDDD), which, from 2026, is intended to require comprehensive compliance with human rights and environmental standards throughout the value chain. Large agricultural and food companies must therefore demonstrate that their suppliers do not destroy local livelihoods, such as access to clean drinking water or fertile land. For investors, these developments are creating a range of opportunities around an emerging megatrend. Allocating a portion of a portfolio to the food, beverage and crop science sectors may therefore make sense.
Read








